Fabián Moreno
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fabián Moreno has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- David Vásquez
Drug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Santiago 8380492, Chile
1 shared publication - Gerardo González-Rocha
Laboratorio de Investigación en Agentes Antibacterianos (LIAA), Departamento de Microbiología, Facultad de Ciencias Biológicas, Universidad de Concepción, Concepción 4070409, Chile
1 shared publication - Ian Burbulis
Facultad de Medicina y Ciencia, Centro de Investigación Biomédica, Universidad San Sebastián, Sede Patagonia, Lago Panguipulli 1390, Puerto Montt 5480000, Región de Los Lagos, Chile
1 shared publication - Javier Campanini-Salinas
Laboratorio Institucional, Universidad San Sebastián, Puerto Montt 5501842, Chile
1 shared publication - Juan Andrades-Lagos
Drug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Sergio Livingstone 1007, Santiago 8380492, Chile
1 shared publication - Nicolás Hinojosa
Drug Development Laboratory, Faculty of Chemical and Pharmaceutical, Sciences, Universidad de Chile, Sergio Livingstone 1007, Santiago 8380492, Chile
1 shared publication
Latest Publications
- Open Access
- 21 May 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (6) , 614
New Quinone Antibiotics against Methicillin-Resistant S. aureus
There is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC® 43300), methicillin-sensitive S. aureus (ATCC® 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development.
- 21 May 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (6) , 614
Open AccessNew Quinone Antibiotics against Methicillin-Resistant S. aureus
There is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC® 43300), methicillin-sensitive S. aureus (ATCC® 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development.